2.14 References 總表
指引（Guidelines）
2026 ACC/AHA/Multisociety Dyslipidemia Guideline (Circulation)
2026 Guideline (JACC)
2026 Dyslipidemia Guideline-at-a-Glance (JACC)
2026 Dyslipidemia Guideline Hub (JACC)
2026 ACC/AHA Press Release
2026 NLA Announcement
2026 ACC/AHA Lipid Calculator (AI-HEART)
2025 ESC/EAS Focused Update (Eur Heart J)
2025 ESC/EAS (ESC Official)
2025 ESC/EAS (Atherosclerosis)
2025 ESC/EAS (EAS Society)
2025 Taiwan Consensus on Cholesterol Management (PMC)
2022 Taiwan Lipid Guidelines for Primary Prevention (J Formos Med Assoc)
2022 Taiwan Focused Update for High-Risk Patients (J Formos Med Assoc)
2022 Taiwan Focused Update PDF (TLAS)
KDIGO 2024 CKD Guideline (PDF)
IAS 2023 FH Best Practice (Nat Rev Cardiol)
Landmark RCTs — Statin
JUPITER (NEJM 2008)
REPRIEVE — pitavastatin in HIV (NEJM 2023)
Landmark RCTs — Non-statin LDL Lowering
IMPROVE-IT (NEJM 2015)
FOURIER — evolocumab (NEJM 2017)
ODYSSEY OUTCOMES — alirocumab (NEJM 2018)
ORION-10 & 11 — inclisiran (NEJM 2020)
CLEAR Outcomes — bempedoic acid (NEJM 2023)
Landmark RCTs — Triglyceride / Omega-3
REDUCE-IT — icosapent ethyl (NEJM 2019)
STRENGTH (JAMA 2020)
PROMINENT — pemafibrate (NEJM 2022)
Landmark RCTs — Lp(a) / HoFH
OCEAN(a)-DOSE — olpasiran (NEJM 2022)
ELIPSE HoFH — evinacumab (NEJM 2020)
台灣藥物與資料查詢
食藥署西藥許可證查詢
中央健保署藥品代碼查詢
台灣動脈硬化暨血管病學會 (TLAS)
⚠️ 免責聲明：本整理為臨床知識複習用途，實際處方需依個別病人狀況、共病、藥物交互作用、健保給付狀態與最新指引調整，並由醫師判斷。商品名與健保給付以衛福部食藥署許可證與健保署公告為準。
